| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:13 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Monkey sp., Rat | 0.1 | KE:386 | Decrease of neuronal network function |
| AOP:15 | Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations | Genetic disease | WPHA/WNT Endorsed | Mus musculus, Drosophila melanogaster, Oryzias latipes, Syrian golden hamster | 0.25 | KE:155 | Inadequate DNA repair |
| AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental disorder of mental health | WPHA/WNT Endorsed | Rat, Mouse, Human | 0.3 | KE:1493 | Increased Pro-inflammatory mediators |
| KE:1492 | Tissue resident cell activation | ||||||
| KE:386 | Decrease of neuronal network function | ||||||
| AOP:23 | Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish) | Unclassified | WPHA/WNT Endorsed | Pimephales promelas | 0.3 | KE:274 | Reduction, Testosterone synthesis by ovarian theca cells |
| KE:219 | Reduction, Plasma 17beta-estradiol concentrations | ||||||
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:25 | Aromatase inhibition leading to reproductive dysfunction | Unclassified | WPHA/WNT Endorsed | Fathead minnow, Medaka, Zebrafish | 0.25 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:34 | LXR activation leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.08 | KE:89 | Synthesis, De Novo Fatty Acid (FA) | |
| AOP:39 | Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response | Respiratory system disease | Under Development | Human, Mouse | 0.2 | KE:272 | Activation/Proliferation, T-cells |
| AOP:40 | Covalent Protein binding leading to Skin Sensitisation | Integumentary system disease | WPHA/WNT Endorsed | Mouse, Human | 0.2 | KE:272 | Activation/Proliferation, T-cells |
| AOP:48 | Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Rat | 0.11 | KE:618 | Decreased, Neuronal network function in adult brain |
| AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental disorder of mental health | WPHA/WNT Endorsed | Homo sapiens, Rattus sp. | 0.4 | KE:280 | Thyroxine (T4) in neuronal tissue, Decreased |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| KE:386 | Decrease of neuronal network function | ||||||
| AOP:58 | NR1I3 (CAR) suppression leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | Human, Mouse, Rat | 0.06 | KE:458 | Increased, De Novo FA synthesis |
| AOP:73 | Xenobiotic Inhibition of Dopamine-beta-Hydroxylase and subsequent reduced fecundity | Unclassified | - | 0.23 | KE:529 | Decreased, GnRH cfos activity | |
| KE:10059 | Decreased LH surge for 24 hours | ||||||
| KE:531 | Decreased, LH Surge | ||||||
| AOP:78 | Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1 | Unclassified | - | Honey bee | 0.12 | KE:386 | Decrease of neuronal network function |
| AOP:80 | Nicotinic acetylcholine receptor activation contributes to accumulation of damaged mitochondrial DNA and leads to colony loss/failure | Unclassified | - | Honey bee | 0.12 | KE:664 | Overwhelmed, Mitochondrial DNA repair mechanisms |
| AOP:90 | Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2 | Unclassified | - | Honey bee | 0.12 | KE:386 | Decrease of neuronal network function |
| AOP:105 | Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary system disease | - | Rattus norvegicus | 0.17 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
| AOP:107 | Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | Cancer; Gastrointestinal system disease | Under Review | Rattus norvegicus, Mus musculus | 0.4 | KE:1214 | Altered gene expression specific to CAR activation, Hepatocytes |
| KE:716 | Increase, cell proliferation (hepatocytes) | ||||||
| AOP:108 | Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | - | Mus musculus, Rattus norvegicus | 0.17 | KE:768 | Increase, Cytotoxicity |
| AOP:109 | Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse) | Cancer; Respiratory system disease | - | Mus musculus | 0.2 | KE:734 | Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) |
| AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.43 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| KE:739 | Increase, Hypertrophy and proliferation (follicular cell) | ||||||
| AOP:114 | HPPD inhibition leading to corneal papillomas and carcinomas (in rat) | Cancer | - | Rattus norvegicus | 0.33 | KE:778 | Increase, Regenerative cell proliferation (corneal cells) |
| KE:777 | Increase, Inflammation (corneal cells) | ||||||
| AOP:115 | Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat) | Cancer | - | Mus musculus, Rattus norvegicus | 0.4 | KE:149 | Increase, Inflammation |
| KE:781 | Increase, Regenerative cell proliferation (forestomach epithelial cells) | ||||||
| AOP:116 | Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary system disease | - | Rattus norvegicus | 0.25 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
| AOP:117 | Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | Under Development | Mus musculus, Rattus norvegicus | 0.25 | KE:716 | Increase, cell proliferation (hepatocytes) |
| AOP:120 | Inhibition of 5α-reductase leading to Leydig cell tumors (in rat) | Cancer; Reproductive system disease | - | Rattus norvegicus, Mus musculus | 0.2 | KE:1690 | Decrease, circulating testosterone levels |
| AOP:121 | Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat) | Cancer; Urinary system disease | - | Mus musculus, Rattus norvegicus | 0.2 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
| AOP:122 | Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation | Unclassified | - | Pimephales promelas | 0.2 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:123 | Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription | Unclassified | - | Pimephales promelas | 0.18 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:126 | Alpha-noradrenergic antagonism leads to reduced fecundity via delayed ovulation | Unclassified | - | 0.23 | KE:529 | Decreased, GnRH cfos activity | |
| KE:10059 | Decreased LH surge for 24 hours | ||||||
| KE:531 | Decreased, LH Surge | ||||||
| AOP:136 | Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors | Benign neoplasm; Respiratory system disease | Under Review | 0.29 | KE:768 | Increase, Cytotoxicity | |
| KE:870 | Increase, Cell Proliferation | ||||||
| AOP:144 | Endocytic lysosomal uptake leading to liver fibrosis | Gastrointestinal system disease | Under Review | Human, Mouse, Rat | 0.22 | KE:1493 | Increased Pro-inflammatory mediators |
| KE:1494 | Leukocyte recruitment/activation | ||||||
| AOP:149 | Peptide Oxidation Leading to Hypertension | Cardiovascular system disease | Under Development | Human, Mouse, Rat, Cow | 0.2 | KE:927 | KE1 : S-Glutathionylation, eNOS |
| KE:933 | KE6 : Depletion, Nitric Oxide | ||||||
| AOP:155 | Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Fathead minnow, Zebrafish | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
| AOP:156 | Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.17 | KE:1003 | Decreased, Triiodothyronine (T3) |
| AOP:164 | Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse | Cancer; Reproductive system disease | - | CD-1 mouse, SD rat | 0.17 | KE:1042 | Proliferation/Clonal Expansion, smooth muscle |
| AOP:173 | Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis | Musculoskeletal system disease; Respiratory system disease | WPHA/WNT Endorsed | Human, Mouse, Rat | 0.12 | KE:1497 | Increased, recruitment of inflammatory cells |
| AOP:176 | Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.4 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:190 | Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.33 | KE:1116 | Decreased, Triiodothyronine (T3) in tissues |
| KE:1829 | Altered, Thyroid hormone-dependent gene expression | ||||||
| AOP:191 | Type III iodotyrosine deiodinase (DIO3) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.5 | KE:1154 | Increased, Triiodothyronine (T3) in tissues |
| KE:1829 | Altered, Thyroid hormone-dependent gene expression | ||||||
| AOP:192 | Pendrin inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.5 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:193 | Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.5 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:194 | Hepatic nuclear receptor activation leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.33 | KE:961 | Increased, Clearance of thyroxine from serum |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:195 | 5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase | Unclassified | - | Argopecten irradians, Mercenaria mercenaria, Arctica islandica, Spisula solidissima, Anodonta cygnea, Dreissena polymorpha | 0.12 | KE:1163 | Increased, Reproductive Success |
| AOP:206 | Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis | Musculoskeletal system disease; Respiratory system disease | Under Development | Homo sapiens | 0.17 | KE:149 | Increase, Inflammation |
| AOP:209 | Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP | Gastrointestinal system disease | - | 0.12 | KE:1287 | Glutathione synthesis | |
| AOP:213 | Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) | Gastrointestinal system disease; Inherited metabolic disorder | - | Vertebrates | 0.17 | KE:1115 | Increase, Reactive oxygen species |
| AOP:218 | Inhibition of CYP7B activity leads to decreased reproductive success via decreased locomotor activity | Unclassified | - | Japanese quail, Cynops pyrrhogaster | 0.17 | KE:1141 | Decreased, Reproductive Success |
| AOP:219 | Inhibition of CYP7B activity leads to decreased reproductive success via decreased sexual behavior | Unclassified | - | Japanese quail, Cynops pyrrhogaster | 0.33 | KE:1390 | Sexual behavior, decreased |
| KE:1141 | Decreased, Reproductive Success | ||||||
| AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal system disease | WPHA/WNT Endorsed | Rodents, Homo sapiens | 0.4 | KE:1393 | Hepatocytotoxicity |
| KE:1394 | Induction, persistent proliferation/sustained proliferation | ||||||
| AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.29 | KE:155 | Inadequate DNA repair |
| KE:870 | Increase, Cell Proliferation | ||||||
| AOP:277 | Impaired IL-1R1 signaling leading to Impaired T-Cell Dependent Antibody Response | Immune system disease | WPHA/WNT Endorsed | Homo sapiens, Mus musculus, Rattus norvegicus | 0.25 | KE:202 | Inhibition, Nuclear factor kappa B (NF-kB) |
| AOP:278 | IKK complex inhibition leading to liver injury | Unclassified | - | 0.12 | KE:202 | Inhibition, Nuclear factor kappa B (NF-kB) | |
| AOP:280 | α-diketone-induced bronchiolitis obliterans | Musculoskeletal system disease; Respiratory system disease | - | 0.14 | KE:149 | Increase, Inflammation | |
| AOP:286 | Mitochondrial complex III antagonism leading to growth inhibition (1) | Unclassified | - | Lemna minor, Daphnia magna, Danio rerio | 0.25 | KE:1821 | Decrease, Cell proliferation |
| AOP:287 | Mitochondrial complex III antagonism leading to growth inhibition (2) | Unclassified | - | Lemna minor, Daphnia magna, Danio rerio | 0.25 | KE:1825 | Increase, Cell death |
| AOP:288 | Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals) | Endocrine system disease | - | Human, Rat | 0.12 | KE:1690 | Decrease, circulating testosterone levels |
| AOP:289 | Inhibition of 5α-reductase leading to impaired fecundity in female fish | Unclassified | Under Development | Fish | 0.17 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| AOP:290 | Mitochondrial ATP synthase antagonism leading to growth inhibition (1) | Unclassified | - | Daphnia magna | 0.25 | KE:1821 | Decrease, Cell proliferation |
| AOP:291 | Mitochondrial ATP synthase antagonism leading to growth inhibition (2) | Unclassified | - | Daphnia magna | 0.25 | KE:1825 | Increase, Cell death |
| AOP:296 | Oxidative DNA damage leading to chromosomal aberrations and mutations | Genetic disease; Chromosomal disease | WPHA/WNT Endorsed | Human, Mice, Rat, Fish | 0.2 | KE:155 | Inadequate DNA repair |
| AOP:299 | Deposition of energy leading to population decline via DNA oxidation and follicular atresia | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | Mammals | 0.43 | KE:870 | Increase, Cell Proliferation |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| AOP:305 | 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | Rat, Human, Mouse | 0.2 | KE:286 | Altered, Transcription of genes by the androgen receptor |
| AOP:306 | Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | Rat, Human, Mouse | 0.25 | KE:286 | Altered, Transcription of genes by the androgen receptor |
| AOP:309 | Luteinizing hormone receptor antagonism leading to reproductive dysfunction | Unclassified | - | Fish | 0.29 | KE:1693 | Reduction, Plasma progesterone concentration |
| KE:1692 | Reduction, Progesterone synthesis | ||||||
| AOP:311 | Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis | Unclassified | - | Daphnia magna, Fish | 0.14 | KE:1115 | Increase, Reactive oxygen species |
| AOP:315 | Inhibition of JAK3 leading to impairment of T-Cell Dependent Antibody Response | Immune system disease | Under Development | Homo sapiens, Mus musculus | 0.2 | KE:1716 | Blockade of STAT5 phosphorylation |
| AOP:321 | Reduced environmental pH leading to thinner shells in Mytilus edulis | Unclassified | - | 0.09 | KE:10042 | Abnormal development | |
| AOP:335 | AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment | Cancer; Urinary system disease | - | Rat | 0.2 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
| AOP:344 | Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring | Unclassified | Under Development | 0.25 | KE:286 | Altered, Transcription of genes by the androgen receptor | |
| AOP:346 | Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Oreochromis niloticus, Chinook salmon, Fathead minnow, European sea bass | 0.4 | KE:1789 | Reduction, 17beta-estradiol synthesis by the undifferentiated gonad |
| KE:1790 | Increased, Differentiation to Testis | ||||||
| AOP:347 | Toll-like receptor 4 activation and peroxisome proliferator-activated receptor gamma inactivation leading to pulmonary fibrosis | Musculoskeletal system disease; Respiratory system disease | - | 0.22 | KE:1283 | Activation, TGF-beta pathway | |
| KE:1292 | Activation, JNK | ||||||
| AOP:348 | Inhibition of 11β-Hydroxysteroid Dehydrogenase leading to decreased population trajectory | Unclassified | Under Development | Fish | 0.4 | KE:1758 | Impaired, Spermatogenesis |
| KE:406 | decreased, Fertility | ||||||
| AOP:349 | Inhibition of 11β-hydroxylase leading to decresed population trajectory | Unclassified | Under Development | Fish | 0.5 | KE:1798 | Decreased spermatogenesis |
| KE:1835 | Cortisol and 11β-(OH) testosterone decreased | ||||||
| KE:406 | decreased, Fertility | ||||||
| KE:1836 | Decreased plasma Cortisol level | ||||||
| AOP:362 | Immune mediated hepatitis | Gastrointestinal system disease; Immune system disease | - | Homo sapiens, Rat | 0.25 | KE:1817 | Apoptotic cell death |
| KE:1633 | Increase in inflammation | ||||||
| AOP:366 | Competitive binding to thyroid hormone carrier protein transthyretin (TTR) leading to altered amphibian metamorphosis | Unclassified | - | 0.29 | KE:961 | Increased, Clearance of thyroxine from serum | |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:367 | Competitive binding to thyroid hormone carrier protein thyroid binding globulin (TBG) leading to altered amphibian metamorphosis | Unclassified | - | 0.29 | KE:961 | Increased, Clearance of thyroxine from serum | |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:368 | Cytochrome oxidase inhibition leading to increased nasal lesions | Unclassified | - | Rodents, Human | 0.33 | KE:1825 | Increase, Cell death |
| AOP:372 | Androgen receptor antagonism leading to testicular cancer | Endocrine system disease; Reproductive system disease; Cancer | - | 0.2 | KE:286 | Altered, Transcription of genes by the androgen receptor | |
| AOP:376 | Androgen receptor agonism leading to male-biased sex ratio | Unclassified | WPHA/WNT Endorsed | Zebrafish, Medaka, Fathead minnow, Channel catfish, Oreochromis niloticus, Chinook salmon | 0.25 | KE:1790 | Increased, Differentiation to Testis |
| AOP:379 | Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation | Cardiovascular system disease | Under Development | Homo sapiens | 0.14 | KE:1869 | Diminished protective oxidative stress response |
| AOP:382 | Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis | Musculoskeletal system disease; Respiratory system disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:383 | Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis | Gastrointestinal system disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:384 | Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease | Urinary system disease | - | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:386 | Deposition of ionizing energy leading to population decline via inhibition of photosynthesis | Reproductive system disease | - | Lemna minor, Chlamydomonas reinhardtii | 0.12 | KE:1115 | Increase, Reactive oxygen species |
| AOP:387 | Deposition of ionising energy leading to population decline via mitochondrial dysfunction | Reproductive system disease | - | Lemna minor | 0.12 | KE:1115 | Increase, Reactive oxygen species |
| AOP:388 | Deposition of ionising energy leading to population decline via programmed cell death | Reproductive system disease | - | Lemna minor | 0.2 | KE:1864 | Increase, Programmed cell death |
| AOP:397 | Bulky DNA adducts leading to mutations | Genetic disease | Under Development | 0.33 | KE:155 | Inadequate DNA repair | |
| AOP:399 | Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos) | Unclassified | - | Zebrafish | 0.12 | KE:1821 | Decrease, Cell proliferation |
| AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.38 | KE:870 | Increase, Cell Proliferation | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| AOP:410 | GSK3beta inactivation leading to increased mortality via defects in developing inner ear | Unclassified | - | Zebrafish | 0.1 | KE:1825 | Increase, Cell death |
| AOP:413 | Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure | Unclassified | - | Fish, Mice | 0.33 | KE:1607 | Increase, Necrosis |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:431 | Increased tumor necrosis factor (TNF) leading to increased risk of gestational diabetes mellitus (GDM) | Inherited metabolic disorder | - | Human | 0.2 | KE:1952 | Abnormal, Glucose homeostasis |
| AOP:441 | Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation | Congenital nervous system abnormality; Nervous system disease | - | Homo sapiens, Mus musculus musculus, Rattus norvegicus | 0.14 | KE:1262 | Apoptosis |
| AOP:444 | Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability | Unclassified | - | 0.22 | KE:1798 | Decreased spermatogenesis | |
| KE:1365 | Increase, Apoptosis | ||||||
| AOP:449 | Ceramide synthase inhibition leading to neural tube defects | Neural tube defect | - | 0.14 | KE:1502 | Histone deacetylase inhibition | |
| AOP:450 | Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality | Nervous system disease | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.14 | KE:618 | Decreased, Neuronal network function in adult brain |
| AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | Human | 0.33 | KE:870 | Increase, Cell Proliferation |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory system disease | - | 0.09 | KE:1262 | Apoptosis | |
| AOP:457 | Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine | Inherited metabolic disorder | - | Human | 0.33 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | Mouse | 0.33 | KE:1821 | Decrease, Cell proliferation |
| KE:2043 | Decrease, Sonic Hedgehog second messenger production | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:464 | Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits | Nervous system disease | - | 0.05 | KE:1825 | Increase, Cell death | |
| AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | 0.25 | KE:748 | Increased, Estrogen receptor (ER) activity | |
| KE:2050 | Increase, developmental abnormalities | ||||||
| AOP:467 | Knickkopf leading to mortality | Unclassified | - | 0.11 | KE:2050 | Increase, developmental abnormalities | |
| AOP:470 | Deposition of energy leads to abnormal vascular remodeling | Cardiovascular system disease | Under Review | Human, Rat, Mouse, Rabbit | 0.12 | KE:1493 | Increased Pro-inflammatory mediators |
| AOP:475 | Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons | Developmental disorder of mental health | Under Development | Mouse, Rat, Human, Caenorhabditis elegans | 0.12 | KE:386 | Decrease of neuronal network function |
| AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous system disease; Monogenic disease | Under Review | Human, Mouse, Rat, Rhesus monkeys, Rabbit, Guinea pig | 0.2 | KE:155 | Inadequate DNA repair |
| KE:870 | Increase, Cell Proliferation | ||||||
| AOP:482 | Deposition of energy leading to occurrence of bone loss | Musculoskeletal system disease | Under Review | Human, Mouse, Rat, Rhesus monkeys | 0.29 | KE:1825 | Increase, Cell death |
| KE:2245 | Altered Cell Differentiation Signaling | ||||||
| AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental disorder of mental health | Under Review | Mouse, Rat, Rabbit, Dog, Pigs, Cow, Human | 0.12 | KE:1492 | Tissue resident cell activation |
| AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | Mouse | 0.5 | KE:1821 | Decrease, Cell proliferation |
| KE:2043 | Decrease, Sonic Hedgehog second messenger production | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive system disease; Cancer | - | 0.33 | KE:854 | Alterations, Cellular proliferation / hyperplasia | |
| KE:286 | Altered, Transcription of genes by the androgen receptor | ||||||
| KE:1183 | Decreased, Apoptosis (Epithelial Cells) | ||||||
| AOP:496 | Androgen receptor agonism leading to reproduction dysfunction (in zebrafish) | Unclassified | - | Zebrafish | 0.3 | KE:286 | Altered, Transcription of genes by the androgen receptor |
| KE:219 | Reduction, Plasma 17beta-estradiol concentrations | ||||||
| KE:1690 | Decrease, circulating testosterone levels | ||||||
| AOP:499 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.25 | KE:2151 | Disruption, neurotransmitter release |
| AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.29 | KE:1115 | Increase, Reactive oxygen species |
| KE:1262 | Apoptosis | ||||||
| AOP:510 | Demethylation of PPAR promotor leading to vascular disrupting effects | Cardiovascular system disease | - | Human, Mouse, Zebrafish | 0.1 | KE:2165 | Activation of PPAR |
| AOP:518 | Liver X Receptor (LXR) activation leads to liver steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | Vertebrates | 0.2 | KE:89 | Synthesis, De Novo Fatty Acid (FA) |
| AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | Mouse, Rat, Human | 0.2 | KE:2204 | Altered brain morphology |
| AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | Murinae gen. sp. | 0.43 | KE:2206 | Increased, histomorphological alteration of testis |
| KE:1758 | Impaired, Spermatogenesis | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:524 | Gluten-driven immune activation leading to celiac disease in genetically predisposed individuals | Immune system disease; Gastrointestinal system disease | - | Human | 0.11 | KE:2255 | Innate immune response, activation |
| AOP:529 | Perfluorooctanesulfonic acid (PFOS) binding to peroxisome proliferator-activated receptors (PPARs) causes dysregulation of lipid metabolism and subsequent liver steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | Vertebrates, Mouse, Rat, Zebrafish | 0.12 | KE:2224 | Dysregulation of transcriptional expression within PPAR signaling network |
| AOP:532 | Retinoic acid receptor agonism during cerebellar development leading to impaired locomotor function | Unclassified | - | 0.2 | KE:2229 | Cerebellar neuronal differentiation. Decreased | |
| AOP:533 | Retinoic acid receptor antagonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | 0.17 | KE:386 | Decrease of neuronal network function | |
| AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental disorder of mental health | - | Mouse, Human | 0.33 | KE:2151 | Disruption, neurotransmitter release |
| KE:2233 | Decreased, ERαβ heterodimers | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:544 | Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation | Nervous system disease | - | Homo sapiens, Mus musculus | 0.17 | KE:149 | Increase, Inflammation |
| AOP:549 | Aromatase inhibition leads to reproductive toxicity (including growth and developmental toxicity) in adult female zebrafish | Unclassified | - | 0.12 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations | |
| AOP:550 | Increased LMNA gene mutation leading to heart failure | Cardiovascular system disease | - | Human, Mouse, Rat | 0.2 | KE:2066 | Altered Signaling Pathways |
| AOP:564 | DBDPE-induced inhibition of mitochondrial complex Ⅰ leading to population decline via neurotoxicity and metabotoxicity. | Unclassified | - | Zebrafish | 0.18 | KE:2151 | Disruption, neurotransmitter release |
| KE:2301 | Abnormal, Behavior | ||||||
| AOP:569 | Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway | Developmental disorder of mental health | - | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:573 | Inhibition, cytochrome oxidase leads to Increased, pulmonary edema | Respiratory system disease | - | Rodents, Humans | 0.33 | KE:1825 | Increase, Cell death |
| AOP:574 | Inhibition, cytochrome oxidase leads to Loss of olfactory function | Unclassified | - | Rodents, Humans | 0.33 | KE:1825 | Increase, Cell death |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:6 | Antagonist binding to PPARα leading to body-weight loss | Symptom | WPHA/WNT Endorsed | Mus musculus, Homo sapiens, Pimephales promelas, Colinus virginianus, Rattus norvegicus | 0.12 | KE:864 | Decreased, Body Weight |
| AOP:7 | Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female | Reproductive system disease; Endocrine system disease; Reproductive system disease | Under Review | Rat, Mouse, Human | 0.6 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| KE:406 | decreased, Fertility | ||||||
| AOP:19 | Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) | Reproductive system disease | - | 0.4 | KE:286 | Altered, Transcription of genes by the androgen receptor | |
| KE:337 | N/A, Impairment of reproductive capacity | ||||||
| AOP:43 | Disruption of VEGFR Signaling Leading to Developmental Defects | Unclassified | WPHA/WNT Endorsed | Mouse, Zebrafish, Rats, Human | 0.2 | KE:1001 | Increased, Developmental Defects |
| AOP:63 | Cyclooxygenase inhibition leading to reproductive dysfunction | Reproductive system disease | - | Goldfish, Human, Mouse, Rat | 0.2 | KE:675 | Reduced, Reproductive Success |
| AOP:100 | Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of female spawning behavior | Reproductive system disease | - | Goldfish | 0.29 | KE:675 | Reduced, Reproductive Success |
| KE:672 | Reduced, Prostaglandin F2alpha synthesis, ovary | ||||||
| AOP:101 | Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of pheromone release | Reproductive system disease | - | Goldfish | 0.29 | KE:675 | Reduced, Reproductive Success |
| KE:681 | Decreased, Prostaglandin F2alpha synthesis, ovary | ||||||
| AOP:102 | Cyclooxygenase inhibition leading to reproductive dysfunction via interference with meiotic prophase I /metaphase I transition | Reproductive system disease | - | Goldfish, Human, Rat, Mouse | 0.2 | KE:690 | Reduced, Luteinizing hormone (LH), plasma |
| KE:675 | Reduced, Reproductive Success | ||||||
| AOP:103 | Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint | Reproductive system disease | - | Goldfish, Human, Rat, Mouse | 0.2 | KE:690 | Reduced, Luteinizing hormone (LH), plasma |
| KE:675 | Reduced, Reproductive Success | ||||||
| AOP:124 | HMG-CoA reductase inhibition leading to decreased fertility | Reproductive system disease | - | Rattus rattus | 0.5 | KE:807 | Decreased, cholesterol |
| KE:1690 | Decrease, circulating testosterone levels | ||||||
| KE:330 | Decrease, Fertility | ||||||
| AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Homo sapiens | 0.44 | KE:280 | Thyroxine (T4) in neuronal tissue, Decreased |
| KE:402 | Cognitive function, decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | Homo sapiens, Mus musculus | 0.5 | KE:885 | Increase, Cancer |
| KE:155 | Inadequate DNA repair | ||||||
| AOP:196 | Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation | Respiratory system disease | - | 0.11 | KE:1226 | Increased Respiratory irritability and Chronic Cough, | |
| AOP:203 | 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline | Reproductive system disease | - | 0.12 | KE:1141 | Decreased, Reproductive Success | |
| AOP:204 | 5-hydroxytryptamine transporter inhibition leading to increased reproductive success and population increase | Unclassified | - | 0.12 | KE:1163 | Increased, Reproductive Success | |
| AOP:205 | AOP from chemical insult to cell death | Unclassified | - | Vertebrates | 0.33 | KE:1263 | Necrosis |
| KE:1262 | Apoptosis | ||||||
| AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | Rattus rattus, Mus musculus | 0.56 | KE:1493 | Increased Pro-inflammatory mediators |
| KE:1492 | Tissue resident cell activation | ||||||
| KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | ||||||
| KE:1193 | N/A, Breast Cancer | ||||||
| KE:1494 | Leukocyte recruitment/activation | ||||||
| AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | 0.56 | KE:1493 | Increased Pro-inflammatory mediators | |
| KE:1492 | Tissue resident cell activation | ||||||
| KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | ||||||
| KE:1193 | N/A, Breast Cancer | ||||||
| KE:1494 | Leukocyte recruitment/activation | ||||||
| AOP:300 | Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | Under Development | Human, Mouse | 0.2 | KE:402 | Cognitive function, decreased |
| AOP:322 | Alkylation of DNA leading to reduced sperm count | Reproductive system disease | - | 0.6 | KE:155 | Inadequate DNA repair | |
| KE:1365 | Increase, Apoptosis | ||||||
| KE:1757 | Reduce, Sperm count | ||||||
| AOP:345 | Androgen receptor (AR) antagonism leading to decreased fertility in females | Endocrine system disease; Reproductive system disease; Reproductive system disease | Under Development | Mammals | 0.33 | KE:286 | Altered, Transcription of genes by the androgen receptor |
| KE:406 | decreased, Fertility | ||||||
| AOP:392 | Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation | Unclassified | Under Development | Humans | 0.4 | KE:1868 | Hyperinflammation |
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| AOP:398 | Decreased ALDH1A (RALDH) activity leading to decreased fertility via disrupted meiotic initiation of fetal oogonia | Reproductive system disease | Under Development | Mouse, Rat, Human | 0.17 | KE:406 | decreased, Fertility |
| AOP:405 | Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function | Cognitive disorder | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.4 | KE:402 | Cognitive function, decreased |
| KE:386 | Decrease of neuronal network function | ||||||
| AOP:406 | SARS-CoV-2 infection leading to hyperinflammation | Unclassified | - | 0.33 | KE:1869 | Diminished protective oxidative stress response | |
| KE:1868 | Hyperinflammation | ||||||
| AOP:432 | Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia | Hematopoietic system disease; Cancer | - | Homo sapiens, Mus musculus | 0.36 | KE:1493 | Increased Pro-inflammatory mediators |
| KE:1955 | Acute Myeloid Leukemia | ||||||
| KE:155 | Inadequate DNA repair | ||||||
| KE:870 | Increase, Cell Proliferation | ||||||
| AOP:442 | Binding to voltage gate sodium channels during development leads to cognitive impairment | Cognitive disorder | Under Review | Rattus norvegicus, Mouse, Humans | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic disease; Cancer | Under Development | Human and other cells in culture, Human, Mice, Rat, Canine heartworm nematode, Yeast | 0.3 | KE:1982 | metastatic breast cancer |
| KE:155 | Inadequate DNA repair | ||||||
| KE:112 | Antagonism, Estrogen receptor | ||||||
| AOP:468 | Binding of SARS-CoV-2 to ACE2 leads to hyperinflammation (via cell death) | Unclassified | - | 0.38 | KE:1868 | Hyperinflammation | |
| KE:1825 | Increase, Cell death | ||||||
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:477 | Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring | Physical disorder | - | 0.33 | KE:2082 | Hypospadias, increased | |
| AOP:485 | Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition | Cognitive disorder | - | Human | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:486 | Binding to the extracellular protein laminin leading to decreased cognitive function | Cognitive disorder | - | Human | 0.14 | KE:402 | Cognitive function, decreased |
| AOP:492 | Glutathione conjugation leading to reproductive dysfunction via oxidative stress | Reproductive system disease | - | Mammals, Fish | 0.4 | KE:1115 | Increase, Reactive oxygen species |
| KE:406 | decreased, Fertility | ||||||
| AOP:498 | Increased LCN2/iron complex leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.5 | KE:2150 | Neurological disorder |
| KE:191 | Neuronal dysfunction | ||||||
| AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.5 | KE:2150 | Neurological disorder |
| KE:386 | Decrease of neuronal network function | ||||||
| AOP:504 | SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level | Unclassified | - | Mammals | 0.33 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | Vertebrates | 0.5 | KE:885 | Increase, Cancer |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:561 | Aromatase induction leading to estrogen receptor alpha activation via increased estradiol | Unclassified | - | Vertebrates | 0.2 | KE:1065 | Activation, estrogen receptor alpha |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:8 | Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Nervous system disease | Under Development | Rat | 0.44 | KE:961 | Increased, Clearance of thyroxine from serum |
| KE:280 | Thyroxine (T4) in neuronal tissue, Decreased | ||||||
| KE:239 | Activation, Pregnane-X receptor, NR1l2 | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:21 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 | Unclassified | WPHA/WNT Endorsed | Zebrafish, Medaka, Gallus gallus | 0.2 | KE:18 | Activation, AhR |
| AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal system disease | Under Development | Humans | 0.5 | KE:149 | Increase, Inflammation |
| KE:41 | Inhibition, Bile Salt Export Pump (ABCB11) | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:288 | Activation of specific nuclear receptors, Transcriptional change | ||||||
| AOP:30 | Estrogen receptor antagonism leading to reproductive dysfunction | Unclassified | Under Review | Zebra danio, Fathead minnow, Medaka | 0.17 | KE:112 | Antagonism, Estrogen receptor |
| AOP:37 | PPARα activation leading to hepatocellular adenomas and carcinomas in rodents | Cancer; Gastrointestinal system disease | Under Development | Mouse, Rat | 0.4 | KE:716 | Increase, cell proliferation (hepatocytes) |
| KE:227 | Activation, PPARα | ||||||
| AOP:38 | Protein Alkylation leading to Liver Fibrosis | Gastrointestinal system disease | WPHA/WNT Endorsed | Human, Rat | 0.43 | KE:244 | Alkylation, Protein |
| KE:1493 | Increased Pro-inflammatory mediators | ||||||
| KE:1492 | Tissue resident cell activation | ||||||
| AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal system disease | Under Review | Rattus sp. ABTC 42503, Mus sp. 2000082 | 0.8 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
| KE:165 | Activation, Long term AHR receptor driven direct and indirect gene expression changes | ||||||
| KE:853 | Changes/Inhibition, Cellular Homeostasis and Apoptosis | ||||||
| KE:139 | N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects | ||||||
| AOP:60 | NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.17 | KE:471 | Inhibition, FoxA2 | |
| KE:245 | Activation, PXR/SXR | ||||||
| AOP:62 | AKT2 activation leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.5 | KE:486 | systemic inflammation leading to hepatic steatosis | |
| KE:484 | Activation, AKT2 | ||||||
| AOP:69 | Modulation of Adult Leydig Cell Function Subsequent to Decreased Cholesterol Synthesis or Transport in the Adult Leydig Cell | Reproductive system disease | - | Rattus norvegicus, Homo sapiens | 0.4 | KE:645 | Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells |
| KE:642 | Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol | ||||||
| AOP:118 | Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | - | Mus musculus, Rattus norvegicus | 0.5 | KE:786 | Increase, Cytotoxicity (hepatocytes) |
| KE:787 | Increase, Regenerative cell proliferation (hepatocytes) | ||||||
| AOP:119 | Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.57 | KE:279 | Thyroperoxidase, Inhibition |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| KE:739 | Increase, Hypertrophy and proliferation (follicular cell) | ||||||
| AOP:128 | Kidney dysfunction by decreased thyroid hormone | Urinary system disease | Under Development | Sprague-Dawley, Homo sapiens | 0.18 | KE:277 | Thyroid hormone synthesis, Decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:131 | Aryl hydrocarbon receptor activation leading to uroporphyria | Inherited metabolic disorder | WPHA/WNT Endorsed | Mouse, Rat, Human, Japanese quail, Chicken, Herring gull, Common Starling | 0.17 | KE:18 | Activation, AhR |
| AOP:150 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF | Unclassified | WPHA/WNT Endorsed | Chicken, Zebrafish, Mouse, Rattus norvegicus | 0.14 | KE:18 | Activation, AhR |
| AOP:151 | AhR activation leading to preeclampsia | Cardiovascular system disease | Under Development | Homo sapiens, Mus musculus | 0.14 | KE:18 | Activation, AhR |
| AOP:157 | Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.33 | KE:1009 | Inhibition, Deiodinase 1 |
| KE:1003 | Decreased, Triiodothyronine (T3) | ||||||
| AOP:158 | Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.33 | KE:1009 | Inhibition, Deiodinase 1 |
| KE:1003 | Decreased, Triiodothyronine (T3) | ||||||
| AOP:159 | Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.5 | KE:279 | Thyroperoxidase, Inhibition |
| KE:1003 | Decreased, Triiodothyronine (T3) | ||||||
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:175 | Thyroperoxidase inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.75 | KE:279 | Thyroperoxidase, Inhibition |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:188 | Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.6 | KE:1152 | Inhibition, Iodotyrosine deiodinase (IYD) |
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:189 | Type I iodothyronine deiodinase (DIO1) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.75 | KE:1116 | Decreased, Triiodothyronine (T3) in tissues |
| KE:1009 | Inhibition, Deiodinase 1 | ||||||
| KE:1003 | Decreased, Triiodothyronine (T3) | ||||||
| AOP:201 | Juvenile hormone receptor agonism leading to male offspring induction associated population decline | Unclassified | - | Daphnia magna, Daphnia pulex | 0.17 | KE:1205 | Activation, Juvenile hormone receptor |
| AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive system disease | - | Caenorhabditis elegans | 0.62 | KE:1115 | Increase, Reactive oxygen species |
| KE:1279 | Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK | ||||||
| KE:1262 | Apoptosis | ||||||
| KE:1174 | Activation, NADPH Oxidase | ||||||
| KE:1281 | Increased, DNA Damage-Repair | ||||||
| AOP:232 | NFE2/Nrf2 repression to steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.12 | KE:1417 | NFE2/Nrf2 repression | |
| AOP:258 | Renal protein alkylation leading to kidney toxicity | Urinary system disease | Under Development | Human, Rat, Mouse | 0.2 | KE:244 | Alkylation, Protein |
| AOP:263 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Mouse, Rat, Lemna minor, Human, Caenorhabditis elegans | 0.5 | KE:1821 | Decrease, Cell proliferation |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:264 | Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation | |
| AOP:265 | Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation | |
| AOP:266 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity | Unclassified | Under Development | 0.17 | KE:1446 | Decrease, Coupling of oxidative phosphorylation | |
| AOP:267 | Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion | Unclassified | Under Development | 0.4 | KE:1821 | Decrease, Cell proliferation | |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:268 | Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation | |
| AOP:270 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired locomotor activity | Unclassified | - | 0.12 | KE:10008 | Increased transcription for detoxification and repair mechanism | |
| AOP:271 | Inhibition of thyroid peroxidase leading to impaired fertility in fish | Unclassified | Under Development | Fish | 0.6 | KE:279 | Thyroperoxidase, Inhibition |
| KE:219 | Reduction, Plasma 17beta-estradiol concentrations | ||||||
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| AOP:274 | Histone deacetylase inhibition leads to impeded craniofacial development | Musculoskeletal system disease | - | 0.25 | KE:1502 | Histone deacetylase inhibition | |
| AOP:275 | Histone deacetylase inhibition leads to neural tube defects | Neural tube defect | - | 0.6 | KE:1560 | Altered differentiation | |
| KE:1502 | Histone deacetylase inhibition | ||||||
| KE:1503 | Histone acetylation, increase | ||||||
| AOP:282 | Adverse outcome pathway on photochemical toxicity initiated by light exposure | Unclassified | Under Review | Human | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:298 | Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer via chronic ROS | Cancer; Gastrointestinal system disease | Under Review | Homo sapiens | 0.33 | KE:1753 | Chronic reactive oxygen species |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:310 | Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR | Unclassified | - | Zebrafish | 0.25 | KE:18 | Activation, AhR |
| KE:219 | Reduction, Plasma 17beta-estradiol concentrations | ||||||
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:314 | Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE) | Immune system disease; Musculoskeletal system disease | Under Development | Homo sapiens | 0.2 | KE:1710 | Binding to estrogen receptor (ER)-α in immune cells |
| AOP:318 | Glucocorticoid Receptor activation leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.2 | KE:122 | Activation, Glucocorticoid Receptor | |
| AOP:323 | PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone | Unclassified | - | Teleost fish | 0.5 | KE:227 | Activation, PPARα |
| KE:1758 | Impaired, Spermatogenesis | ||||||
| KE:807 | Decreased, cholesterol | ||||||
| AOP:324 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death | Unclassified | - | Fish | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:325 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death | Unclassified | - | Fish | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:326 | Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell death | Unclassified | - | Fish | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:327 | Excessive reactive oxygen species production leading to mortality (1) | Unclassified | - | Daphnia magna | 0.4 | KE:1115 | Increase, Reactive oxygen species |
| KE:1769 | Increase, Body fluid overload | ||||||
| AOP:328 | Excessive reactive oxygen species production leading to mortality (2) | Unclassified | - | Daphnia magna | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:329 | Excessive reactive oxygen species production leading to mortality (3) | Unclassified | - | Daphnia magna, Paracyclopina nana | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:330 | Excessive reactive oxygen species production leading to mortality (4) | Unclassified | - | Daphnia magna | 0.4 | KE:1365 | Increase, Apoptosis |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:331 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and reduced cell proliferation | Unclassified | - | Daphnia magna, Daphnia middendorffiana, Daphnia pulex, Daphnia pulicaria, Daphnia parvula | 0.5 | KE:1821 | Decrease, Cell proliferation |
| KE:1505 | Cell cycle, disrupted | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:332 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation | Unclassified | - | 0.6 | KE:1821 | Decrease, Cell proliferation | |
| KE:1505 | Cell cycle, disrupted | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:333 | Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation | Unclassified | - | 0.6 | KE:1821 | Decrease, Cell proliferation | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:334 | Glucocorticoid Receptor Agonism Leading to Impaired Fin Regeneration | Unclassified | - | Teleost fish | 0.33 | KE:122 | Activation, Glucocorticoid Receptor |
| KE:2245 | Altered Cell Differentiation Signaling | ||||||
| AOP:363 | Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure | Unclassified | Under Review | Zebrafish | 0.5 | KE:279 | Thyroperoxidase, Inhibition |
| KE:1003 | Decreased, Triiodothyronine (T3) | ||||||
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:364 | Thyroperoxidase inhibition leading to altered visual function via decreased eye size | Unclassified | Under Development | 0.5 | KE:279 | Thyroperoxidase, Inhibition | |
| KE:1003 | Decreased, Triiodothyronine (T3) | ||||||
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:365 | Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning | Unclassified | Under Development | 0.5 | KE:279 | Thyroperoxidase, Inhibition | |
| KE:1003 | Decreased, Triiodothyronine (T3) | ||||||
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| AOP:414 | Aryl hydrocarbon receptor activation leading to lung fibrosis through TGF-β dependent fibrosis toxicity pathway | Musculoskeletal system disease; Respiratory system disease | - | 0.2 | KE:18 | Activation, AhR | |
| AOP:415 | Aryl hydrocarbon receptor activation leading to lung fibrosis through IL-6 toxicity pathway | Musculoskeletal system disease; Respiratory system disease | - | 0.2 | KE:18 | Activation, AhR | |
| AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.33 | KE:18 | Activation, AhR | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:417 | Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway | Cancer | - | 0.4 | KE:18 | Activation, AhR | |
| KE:17 | Altered gene expression, AHR nuclear translocator (ARNT)-dependent pathway | ||||||
| AOP:418 | Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway | Respiratory system disease | - | 0.8 | KE:18 | Activation, AhR | |
| KE:1825 | Increase, Cell death | ||||||
| KE:17 | Altered gene expression, AHR nuclear translocator (ARNT)-dependent pathway | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory system disease | - | 0.5 | KE:18 | Activation, AhR | |
| KE:1262 | Apoptosis | ||||||
| AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.5 | KE:18 | Activation, AhR | |
| KE:870 | Increase, Cell Proliferation | ||||||
| AOP:438 | reactive oxygen species generation leading to increased cardiovascular morbidity and mortality | Cardiovascular system disease | - | 0.08 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:445 | Estrogen Receptor Alpha Agonism leads to Impaired Reproduction | Reproductive system disease | - | 0.25 | KE:1065 | Activation, estrogen receptor alpha | |
| KE:1987 | Decreased, Androgen and Progestin | ||||||
| AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory system disease | - | 0.3 | KE:1115 | Increase, Reactive oxygen species | |
| KE:165 | Activation, Long term AHR receptor driven direct and indirect gene expression changes | ||||||
| KE:18 | Activation, AhR | ||||||
| KE:149 | Increase, Inflammation | ||||||
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:447 | Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways | Urinary system disease | - | 0.25 | KE:202 | Inhibition, Nuclear factor kappa B (NF-kB) | |
| KE:1365 | Increase, Apoptosis | ||||||
| KE:1633 | Increase in inflammation | ||||||
| AOP:448 | ROS, inflammation, and activation of nAChR lead to increased incidence of cardiovascular morbidity and mortality | Cardiovascular system disease | - | 0.12 | KE:2004 | Increased, secretion of catecholamine | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:453 | Reactive oxygen species and subsequent oxidative stress lead to increased incidence of digestive morbidity and mortality in the general population | Gastrointestinal system disease | - | 0.08 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:455 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development | Musculoskeletal system disease | Under Review | Zebrafish, Mouse, Human, Sebastiscus marmoratus, Salmo salar, Chicken | 0.17 | KE:18 | Activation, AhR |
| AOP:456 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity | Unclassified | Under Review | Zebrafish, Mouse, Human, Chicken | 0.17 | KE:18 | Activation, AhR |
| AOP:469 | Reactive oxygen speicies overproduction leading to increased digestive morbidity and mortality in generation population | Gastrointestinal system disease | - | 0.08 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:472 | DNA adduct formation leading to kidney failure | Urinary system disease | - | 0.33 | KE:1825 | Increase, Cell death | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:149 | Increase, Inflammation | ||||||
| AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired metabolic disease | - | Mus musculus, Homo sapiens | 0.3 | KE:2126 | Estrogen receptor alpha inactivation |
| KE:1633 | Increase in inflammation | ||||||
| KE:1497 | Increased, recruitment of inflammatory cells | ||||||
| AOP:494 | AhR activation leading to liver fibrosis | Gastrointestinal system disease | - | Mus musculus, Homo sapiens | 0.17 | KE:18 | Activation, AhR |
| AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited metabolic disorder; Disease of metabolism | - | 0.25 | KE:2126 | Estrogen receptor alpha inactivation | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:507 | Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway | Cardiovascular system disease | - | Mouse, Zebrafish, Human | 0.17 | KE:1417 | NFE2/Nrf2 repression |
| AOP:508 | Nrf2 inhibition leading to vascular disrupting effects through activating HIF1α, Semaphorin 6A, and Dll4-Notch pathway | Cardiovascular system disease | - | Mouse, Zebrafish, Human | 0.14 | KE:1417 | NFE2/Nrf2 repression |
| AOP:509 | Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction | Cardiovascular system disease | - | 0.29 | KE:1417 | NFE2/Nrf2 repression | |
| KE:1365 | Increase, Apoptosis | ||||||
| AOP:511 | The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects | Cardiovascular system disease | - | Human, Mouse, Zebrafish | 0.06 | KE:1115 | Increase, Reactive oxygen species |
| AOP:517 | Pregnane X Receptor (PXR) activation leads to liver steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | Vertebrates | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
| AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | 0.08 | KE:2216 | Binding of antagonist to thyroid hormone receptor | |
| AOP:536 | Estrogen receptor agonism leading to reduced survival and population growth due to renal failure | Unclassified | - | 0.17 | KE:111 | Agonism, Estrogen receptor | |
| AOP:537 | Estrogen receptor agonism leads to reduced fecundity via increased vitellogenin in the liver | Unclassified | - | 0.2 | KE:111 | Agonism, Estrogen receptor | |
| AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.33 | KE:1115 | Increase, Reactive oxygen species | |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:541 | Excessive ROS generation leading to increased incidence of vascular calcification by VSMC phenotype switching | Cardiovascular system disease | - | 0.15 | KE:1493 | Increased Pro-inflammatory mediators | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:545 | Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased cholesterol synthesis | Unclassified | - | Mammals | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
| AOP:548 | Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased PCSK9 protein expression | Unclassified | - | Mammals | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
| AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive system disease; Endocrine system disease | - | Rat, Mouse, Zebra fish, Human | 0.33 | KE:18 | Activation, AhR |
| KE:1262 | Apoptosis |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:18 | PPARα activation in utero leading to impaired fertility in males | Reproductive system disease | Under Review | Human, Rat, Mouse | 0.5 | KE:227 | Activation, PPARα |
| KE:413 | Reduction, Testosterone synthesis in Leydig cells | ||||||
| KE:1690 | Decrease, circulating testosterone levels | ||||||
| KE:406 | decreased, Fertility | ||||||
| AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.62 | KE:402 | Cognitive function, decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:280 | Thyroxine (T4) in neuronal tissue, Decreased | ||||||
| KE:279 | Thyroperoxidase, Inhibition | ||||||
| AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive system disease | - | Rattus norvegicus | 1.0 | KE:413 | Reduction, Testosterone synthesis in Leydig cells |
| KE:1690 | Decrease, circulating testosterone levels | ||||||
| KE:495 | Repressed expression of steroidogenic enzymes | ||||||
| KE:494 | Glucocorticoid Receptor Agonist, Activation | ||||||
| KE:406 | decreased, Fertility | ||||||
| KE:520 | Decreased sperm quantity or quality in the adult, Decreased fertility | ||||||
| KE:496 | Increased apoptosis, decreased fetal/adult Leydig Cells | ||||||
| AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive system disease; Cancer | - | Rattus norvegicus | 0.83 | KE:111 | Agonism, Estrogen receptor |
| KE:749 | Decreased, Progesterone from corpus luteum | ||||||
| KE:746 | Increase, Dopaminergic activity | ||||||
| KE:772 | Increase, Hyperplasia (glandular epithelial cells of endometrium) | ||||||
| KE:773 | Increase, Endometrial adenocarcinomas | ||||||
| AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive system disease; Cancer | - | Mouse, Homo sapiens | 1.0 | KE:1070 | Increased, adenosquamous carcinomas of endometrium |
| KE:1069 | Increased, Hyperplasia (glandular epithelial cells of endometrium) | ||||||
| KE:1067 | Proliferation/Clonal Expansion, aberrant basal cells | ||||||
| KE:1065 | Activation, estrogen receptor alpha | ||||||
| KE:1064 | prepubertal increase, Estrogen receptor (ER) activity | ||||||
| KE:1066 | Promotion, SIX-1 postive basal-type progenitor cells | ||||||
| KE:1068 | squamous metaplasia, aberrant basal cells | ||||||
| AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive system disease | WPHA/WNT Endorsed | Rat, Human, Mouse | 0.83 | KE:1503 | Histone acetylation, increase |
| KE:1506 | Testicular atrophy | ||||||
| KE:1505 | Cell cycle, disrupted | ||||||
| KE:1262 | Apoptosis | ||||||
| KE:1502 | Histone deacetylase inhibition | ||||||
| AOP:269 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired growth and development | Unclassified | - | 0.33 | KE:10008 | Increased transcription for detoxification and repair mechanism | |
| KE:10013 | Impaired growth and development | ||||||
| AOP:423 | Toxicological mechanisms of hepatocyte apoptosis through the PARP1 dependent cell death pathway | Unclassified | - | 0.33 | KE:1817 | Apoptotic cell death | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic disease; Cancer | Under Development | Humans, Mice | 0.67 | KE:18 | Activation, AhR |
| KE:1971 | Increased, tumor growth | ||||||
| KE:1982 | metastatic breast cancer | ||||||
| KE:149 | Increase, Inflammation | ||||||
| KE:1241 | Increased, Motility | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:440 | Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia | Benign neoplasm; Endocrine system disease; Reproductive system disease; Reproductive system disease; Cancer; Endocrine system disease | Under Development | Human, Rat, Mice | 0.33 | KE:1046 | Suppression, Estrogen receptor (ER) activity |
| KE:1973 | Increased, estrogens | ||||||
| KE:2092 | Promotion, Ovarian Cancer | ||||||
| AOP:458 | AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Rat, Mouse, Monkey, Human | 0.62 | KE:402 | Cognitive function, decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| KE:280 | Thyroxine (T4) in neuronal tissue, Decreased | ||||||
| KE:18 | Activation, AhR | ||||||
| KE:961 | Increased, Clearance of thyroxine from serum | ||||||
| AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | - | Human, Mouse, Rat | 0.56 | KE:402 | Cognitive function, decreased |
| KE:281 | Thyroxine (T4) in serum, Decreased | ||||||
| KE:277 | Thyroid hormone synthesis, Decreased | ||||||
| KE:280 | Thyroxine (T4) in neuronal tissue, Decreased | ||||||
| KE:18 | Activation, AhR | ||||||
| AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal system disease | - | 0.36 | KE:2034 | liver dysfunction | |
| KE:149 | Increase, Inflammation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive disorder | - | Human | 0.43 | KE:1869 | Diminished protective oxidative stress response |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:402 | Cognitive function, decreased | ||||||
| AOP:503 | Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation | Reproductive system disease; Cancer | Under Review | Human, Mouse | 0.5 | KE:2154 | Uterine adenocarcinoma (endometrioid adenocarcinoma Type I) |
| KE:1065 | Activation, estrogen receptor alpha | ||||||
| KE:772 | Increase, Hyperplasia (glandular epithelial cells of endometrium) | ||||||
| AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | Human, Mouse, Rat | 0.6 | KE:885 | Increase, Cancer |
| KE:149 | Increase, Inflammation | ||||||
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | Human, Mouse, Rat | 0.6 | KE:885 | Increase, Cancer |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1060 | Alteration, lipid metabolism |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.